Role of pharmacy channel in adherence to hepatitis C regimens

American Journal of Pharmacy Benefits

Volumn 5, Issue 1, 2013, Pages 17-25

  Visaria, Jay ^a   Frazee, Sharon Glave ^a  

^a Express Scripts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; DEPRESSION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; PHARMACY; PHARMACY BENEFIT MANAGER; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; TREATMENT DURATION;

EID: 84873911363     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 144(10):705-714.
2. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology. 2002 36(5)(suppl 1):S3-S20.
3. DiBonaventura MD, Wagner J-S, Yuan Y, L'Italien G, Langley P, Ray Kim W. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ. 2010 13(4):709-718.
4. McCombs JS, Yuan Y, Shin J, Saab S. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther. 2011 33(9):1268-1280.
5. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. Allcause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm. 2011 17(7):531-546.
6. DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray Kim W. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ. 2011 14(2):253-261.
7. Brok J, Gluud LL, Gluud C. Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev. 2010 (1):CD005445.
8. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123(4):1061-1069.
9. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 54(4):1433-1444.
10. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care. 2005 11(10)(suppl): S296-S306.
11. Opar A. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov. 2010 9(7):501-503.
12. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci. 2006 3(2):57-62
13. Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol. 2009 15(30): 3713-3724.
14. Soriano V, Miralles C, Berdún MA, et al; PRESCO Study Group. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther. 2007 12(4):469-476.
15. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-1492.
16. Hutchinson MK, Holtman MC. Analysis of count data using poisson regression. Res Nurs Health. 2005;28(5):408-418.
17. Egede LE, Gebregziabher M, Hunt KJ, et al. Regional, geographic, and ethnic differences in medication adherence among adults with type 2 diabetes. Ann Pharmacother. 2011 45(2):169-178.
18. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fi xed-dose combination therapy. Clin Ther. 2002 24(3): 460-467.
19. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 353(5): 487-497.
20. Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med. 2011 155(6):353-360.
21. Mitra D, Davis KL, Beam C, Medjedovic J, Rustgi V. Treatment patterns and adherence among patients with chronic hepatitis C virus in a US managed care population. Value Health. 2010 13(4):479-486.
22. Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients' self reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008 28(3):289-293.
23. Shiffman ML, Esteban R. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? Liver Int. 2012 32(suppl 1):54-60.
24. Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat. 2001 8(4):264-269.
25. Missiha S, Heathcote J, Arenovich T, Khan K; Canadian Pegasys Expanded Access Group. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. 2007 102(10):2181-2188.